Antitumor effect of salidroside on mice bearing HepA hepatocellular carcinoma
MetadataShow full item record
AbstractSalidroside, a phenylpropanoid glycoside extracted from Rhodiola rosea L., has antiproliferative effects on tumour cells in mice. However it’s antitumor mechanism remains largely unknown. In this study, 4 groups of mice bearing hepatocarcinoma cells were given treatment with vehicle alone, cyclophosphamide (25 mg/kg, i.p.) and salidroside, either 100 or 200 mg/kg (p.o.) for 14 days. The morphology of tumour specimens was analysed by transmission electron microscopy. Apoptotic cells in sections of mouse tumour tissue were analysed using an in situ apoptosis kit. The expression of Bcl-2, Bax and caspase 3 mRNA were examined with RT-PCR. The results showed that the tumour weights in groups 100 or 200 mg/kg/day of salidroside were reduced significantly (45.34 and 52.48% respectively), compared to vehicle groups. Salidroside increased apoptotic cells index, e.g. in 200 mg/kg group, it was four times higher compared to the control group. Even more, treatment with salidroside decreased Bcl-2 mRNA expression and increased Bax and caspase 3 mRNA expressions. These indicated that the antitumor mechanism of salidroside may induce tumour cell apoptosis in mice by triggering the mitochondrial-dependent pathway and activation of caspase 3.
CitationSong H, Wand J, Wang M , Dong H, Li L, Zhang T, Zhoud S (2015) 'Antitumor effect of salidroside on mice bearing HepA hepatocellular carcinoma', Acta Farmaceutica Bonaerense, 34 (10).
JournalActa Farmaceutica Bonaerense
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-nd/4.0/